Experimental vaccine aims to clear precancerous cervical lesions without surgery
NCT ID NCT07702656
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This trial tests an experimental vaccine called SYS6026 in people with high-grade cervical lesions caused by HPV type 16 or 18. The goal is to see if the vaccine can help the body clear the virus and reverse the lesions, potentially avoiding the need for surgery. Participants are randomly assigned to receive different doses of SYS6026 or a placebo, and their response is monitored over 36 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental therapeutic vaccine called SYS6026
- What this could lead to
- If successful, this could offer a non-surgical treatment option for high-grade cervical lesions caused by HPV16 or 18.
- What could go wrong
- This is an early Phase II trial with a small number of participants, so results may not confirm effectiveness or safety. The treatment may not lead to lesion regression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE CERVICAL INTRAEPITHELIAL LESIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CSPC Megalith Biopharmaceutical Co., Ltd.
Shijiazhuang, Hebei, 050035, China
Contact Phone: •••-•••-•••• Email: •••••@•••••